This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Jan 26;376(4):381-382.

doi: 10.1056/NEJMe1614726.

Bezlotoxumab - A New Agent for Clostridium difficile Infection

John G Bartlett¹

Affiliations

PMID: 28121509
DOI: 10.1056/NEJMe1614726

Editorial

Bezlotoxumab - A New Agent for Clostridium difficile Infection

John G Bartlett. N Engl J Med. 2017.

. 2017 Jan 26;376(4):381-382.

doi: 10.1056/NEJMe1614726.

Author

John G Bartlett¹

Affiliation

¹ From the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.

PMID: 28121509
DOI: 10.1056/NEJMe1614726

No abstract available

PubMed Disclaimer

Comment on

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Clinical Trial.

Similar articles

Bezlotoxumab and Recurrent Clostridium difficile Infection.
Maw A, Shen N, Francis P. Maw A, et al. N Engl J Med. 2017 Apr 20;376(16):1593-4. doi: 10.1056/NEJMc1702531. N Engl J Med. 2017. PMID: 28425276 No abstract available.
Bezlotoxumab and Recurrent Clostridium difficile Infection.
Bartlett JG. Bartlett JG. N Engl J Med. 2017 Apr 20;376(16):1596. doi: 10.1056/NEJMc1702531. N Engl J Med. 2017. PMID: 28423300 No abstract available.
Bezlotoxumab and Recurrent Clostridium difficile Infection.
Sommer H, Timsit JF, Wolkewitz M; COMBACTE-NET Consortium. Sommer H, et al. N Engl J Med. 2017 Apr 20;376(16):1594. doi: 10.1056/NEJMc1702531. N Engl J Med. 2017. PMID: 28423299 No abstract available.
Pathogenesis and treatment of Clostridium difficile infection.
Tonna I, Welsby PD. Tonna I, et al. Postgrad Med J. 2005 Jun;81(956):367-9. doi: 10.1136/pgmj.2004.028480. Postgrad Med J. 2005. PMID: 15937201 Free PMC article. Review.
[Oncologic aspects of Clostridium difficile].
Telekes A. Telekes A. Orv Hetil. 2016 Jul;157(28):1110-6. doi: 10.1556/650.2016.30463. Orv Hetil. 2016. PMID: 27397423 Review. Hungarian.

See all similar articles

Cited by

De novo design of mini-protein binders broadly neutralizing Clostridioides difficile toxin B variants.
Lv X, Zhang Y, Sun K, Yang Q, Luo J, Tao L, Lu P. Lv X, et al. Nat Commun. 2024 Oct 2;15(1):8521. doi: 10.1038/s41467-024-52582-1. Nat Commun. 2024. PMID: 39358329 Free PMC article.
Clostridioides difficile Infection in Hospitalized Patients-A Retrospective Epidemiological Study.
Fonseca F, Forrester M, Advinha AM, Coutinho A, Landeira N, Pereira M. Fonseca F, et al. Healthcare (Basel). 2023 Dec 29;12(1):76. doi: 10.3390/healthcare12010076. Healthcare (Basel). 2023. PMID: 38200982 Free PMC article.
Recurrent Multidrug-Resistant Clostridium difficile Infection Secondary to Ulcerative Colitis a Case Report.
Jaramillo AP, Castells J, Ibrahimli S, Siegel S. Jaramillo AP, et al. Med Sci (Basel). 2023 Aug 16;11(3):52. doi: 10.3390/medsci11030052. Med Sci (Basel). 2023. PMID: 37606431 Free PMC article.
Long-Term Lactulose Administration Improves Dysbiosis Induced by Antibiotic and C. difficile in the PathoGut^TM SHIME Model.
Calatayud M, Duysburgh C, Van den Abbeele P, Franckenstein D, Kuchina-Koch A, Marzorati M. Calatayud M, et al. Antibiotics (Basel). 2022 Oct 24;11(11):1464. doi: 10.3390/antibiotics11111464. Antibiotics (Basel). 2022. PMID: 36358119 Free PMC article.
The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021.
Hyte ML, Arphai LJ, Vaughn CJ, Durham SH. Hyte ML, et al. Antibiotics (Basel). 2022 Sep 7;11(9):1211. doi: 10.3390/antibiotics11091211. Antibiotics (Basel). 2022. PMID: 36139989 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations